ORMP · Oramed Pharmaceuticals Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $2.00M | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | $1.99M | - | - | - | - | - |
| Gross Profit | - | - | - | - | $13.0K | - | - | - | - | - |
| R&D | $1.59M | - | $1.15M | $1.03M | $2.21M | - | $2.24M | $1.44M | $1.18M | - |
| SG&A | $2.06M | - | $1.27M | $1.46M | $2.31M | - | $847.0K | $1.69M | $1.78M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $30.0K | - | - | - | $30.0K | - | - | - | $56.0K | - |
| Operating Income | ($3.66M) | - | ($2.43M) | ($2.49M) | ($4.50M) | - | ($3.09M) | ($3.13M) | ($2.96M) | - |
| Interest Expense | - | - | - | - | $592.0K | - | $826.0K | $261.0K | $592.0K | - |
| Income Tax | $11.13M | - | $11.06M | ($126.0K) | $584.0K | - | $1.13M | $1.63M | - | - |
| Net Income | $38.31M | - | $48.40M | $13.29M | ($7.64M) | - | ($19.62M) | $9.21M | $1.54M | - |
| EPS - Basic | $0.94 | - | $1.16 | $0.32 | ($0.19) | - | ($0.48) | $0.22 | $0.04 | - |
| EPS - Diluted | $0.91 | - | $1.13 | $0.31 | ($0.19) | - | ($0.48) | $0.22 | $0.04 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.20M | $45.95M | $52.18M | $54.42M | $74.52M | $54.42M | $42.10M | $84.75M | $18.58M | $9.05M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $481.0K | $443.0K | $560.0K | $715.0K | $509.0K | $789.0K | - | - | - | $551.0K |
| Current Assets | $68.15M | $133.27M | $136.12M | $99.03M | $131.48M | $143.22M | $142.77M | $153.27M | $177.09M | $162.58M |
| Total Assets | $268.85M | $230.86M | $220.49M | $161.68M | $147.54M | $155.28M | $165.08M | $184.22M | $203.65M | $220.55M |
| Current Liabilities | $10.56M | $19.09M | $6.12M | $3.69M | $5.49M | $5.68M | $5.27M | $3.73M | $33.56M | $53.21M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $238.28M | $199.74M | $203.28M | $154.53M | $140.81M | $146.26M | $156.44M | $177.06M | $166.64M | $163.82M |
| Retained Earnings | ($85.12M) | ($123.44M) | ($122.58M) | ($170.97M) | ($184.26M) | ($176.62M) | ($166.43M) | ($146.81M) | ($156.02M) | ($157.56M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.92M) | - | - | - | ($3.52M) | - | - | - | ($1.48M) | - |
| Investing Cash Flow | ($19.49M) | - | - | - | $23.62M | - | - | - | $30.00M | - |
| Financing Cash Flow | ($10.36M) | - | - | - | - | - | - | - | ($19.00M) | - |
| CapEx | $5.0K | - | - | - | $3.0K | - | - | - | $2.0K | - |
| Free Cash Flow | ($2.92M) | - | - | - | ($3.52M) | - | - | - | ($1.48M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | 0.7% | - | - | - | - | - |
| Operating margin | - | - | - | - | -225.0% | - | - | - | - | - |
| EBITDA margin | - | - | - | - | -223.5% | - | - | - | - | - |
| Net margin | - | - | - | - | -382.1% | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | -176.1% | - | - | - | - | - |
| FCF / Net income | -0.08 | - | - | - | 0.46 | - | - | - | -0.96 | - |
| R&D / Revenue | - | - | - | - | 110.3% | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | 115.3% | - | - | - | - | - |
| Effective tax rate | 22.5% | - | 18.6% | -1.0% | - | - | - | 15.1% | - | - |
| Return on assets | 14.2% | - | 21.9% | 8.2% | -5.2% | - | -11.9% | 5.0% | 0.8% | - |
| Return on equity | 16.1% | - | 23.8% | 8.6% | -5.4% | - | -12.5% | 5.2% | 0.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 6.45 | 6.98 | 22.24 | 26.81 | 23.94 | 25.19 | 27.08 | 41.06 | 5.28 | 3.06 |
| Quick ratio | 6.45 | 6.98 | 22.24 | 26.81 | 23.94 | 25.19 | 27.08 | 41.06 | 5.28 | 3.06 |
| Cash ratio | 1.25 | 2.41 | 8.53 | 14.74 | 13.57 | 9.57 | 7.98 | 22.70 | 0.55 | 0.17 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | -7.6x | - | -3.7x | -12.0x | -5.0x | - |
| Equity multiplier | 1.13 | 1.16 | 1.08 | 1.05 | 1.05 | 1.06 | 1.06 | 1.04 | 1.22 | 1.35 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | 0.01 | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | 94d | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 3.7x | - | 2.3x | 7.3x | - | - | - | 11.7x | 73.0x | - |
| P / B | 0.6x | - | 0.6x | 0.6x | 0.6x | - | 0.6x | 0.6x | 0.7x | - |
| P / S | - | - | - | - | 44.1x | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | 43.7% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | 24.3% | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 18.7% | - | 21.4% | 20.6% | -51.9% | - | -6.8% | 17.3% | 43.1% | - |
| Net income growth (YoY) | - | - | - | 44.2% | - | - | -508.9% | - | - | - |
| EPS growth (YoY) | - | - | - | 40.9% | - | - | - | 633.3% | -85.2% | - |
| EPS CAGR (3y) | 49.9% | - | 75.2% | 37.2% | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 17.1% | - | - | - | -138.3% | - | - | - | 74.3% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 69.2% | 36.6% | 29.9% | -12.7% | -15.5% | -10.7% | 4.9% | 16.8% | 10.4% | 7.9% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ORAMED PHARMACEUTICALS INC. against the 5 most active filers in the same SIC group.
Dividends
$0.25/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Jan 16, 2026 | $0.2500 |